53 research outputs found
Beta-blocker management in patients admitted for acute heart failure and reduced ejection fraction: a review and expert consensus opinion
The role of the beta-adrenergic signaling pathway in heart failure (HF) is pivotal. Early blockade of this pathway with beta-blocker (BB) therapy is recommended as the first-line medication for patients with HF and reduced ejection fraction (HFrEF). Conversely, in patients with severe acute HF (AHF), including those with resolved cardiogenic shock (CS), BB initiation can be hazardous. There are very few data on the management of BB in these situations. The present expert consensus aims to review all published data on the use of BB in patients with severe decompensated AHF, with or without hemodynamic compromise, and proposes an expert-recommended practical algorithm for the prescription and monitoring of BB therapy in critical settings
Remplacement valvulaire aortique percutanĂ© (TAVI) (intĂ©rĂȘt pronostique de l'Ă©valuation gĂ©riatrique en prĂ©-procĂ©dure)
LILLE2-BU Santé-Recherche (593502101) / SudocSudocFranceF
Management of valvulopathies with acute severe heart failure and cardiogenic shock
International audienc
Assistance circulatoire mécanique de courte durée dans le choc cardiogénique en unité de soins intensifs de cardiologie : avis et mise au point du groupe USIC de la SFC endossé par le GACI
International audienceCardiogenic shock (CS) is a major challenge in contemporary cardiology. Despite a better understanding of the pathophysiology of CS, its management has only improved slightly. The prevalence of CS has remained stable over the past decade, but its outcome has seen few improvements, with the 1-month mortality rate still in the range of 40-60%. Inotropes and vasopressors are the first-line therapies for CS, but they are associated with significant hazards, and have well-known deleterious effects. Furthermore, a significant number of patients develop refractory CS with haemodynamic instability, causing critical organ hypoperfusion and/or pulmonary congestion, despite increasing doses of catecholamines. A major change has resulted from the recent advent and availability of potent mechanical circulatory support (MCS) devices. These devices, which ensure sustained blood flow, provide a great and long-awaited opportunity to improve the prognosis of CS. Several efficient MCS devices are now available, including left ventricle-to-aorta circulatory support devices and full pulmonary and circulatory support with venoarterial extracorporeal membrane oxygenation. However, evidence to support their indications, the timing of implantation and the selection of patients and devices is scarce. Because these devices are gaining momentum and are becoming readily available, the "UnitĂ© de Soins Intensifs de Cardiologie" group of the French Society of Cardiology aims to propose practical algorithms for the use of these devices, to help intensive care unit and cardiac care unit physicians in this complex area, where evidence is limited.Le choc cardiogĂ©nique (CC) reste un enjeu majeur de la cardiologie contemporaine. MalgrĂ© une meilleure comprĂ©hension de sa physiopathologie, sa prise en charge nâa que peu Ă©voluĂ©e. Au cours de la derniĂšre dĂ©cennie, sa prĂ©valence est restĂ©e stable mais son pronostic ne sâest que peu amĂ©liorĂ© avec une mortalitĂ© Ă un mois comprise entre 40 % et 60 %. Les inotropes et les vasopresseurs forment la premiĂšre ligne de traitement dans le CC mais ils ont une efficacitĂ© variable et des effets dĂ©lĂ©tĂšres bien connus. De plus un nombre significatif de patients dĂ©veloppent un CC rĂ©fractaire avec une hĂ©modynamique instable et une hypoperfusion dâorgane et/ou une congestion malgrĂ© des doses croissantes de catĂ©cholamines. La mise Ă disposition rĂ©cente de systĂšmes efficaces de support hĂ©modynamique mĂ©canique reprĂ©sente un changement majeur. Ces dispositifs, qui assurent un support au flux sanguin, reprĂ©sentent une grande opportunitĂ©, attendue depuis longtemps, dâamĂ©liorer le pronostic du CC. Il y a aujourdâhui plusieurs systĂšmes de support hĂ©modynamique mĂ©caniques disponibles allant de dispositifs de support circulatoire du ventricule gauche vers lâaorte Ă un support cardio-pulmonaire complet avec les systĂšmes de circulation extracorporelle incluant une membrane dâoxygĂ©nation. Cependant les donnĂ©es concernant leurs indications, leur dĂ©lai dâimplantation, la sĂ©lection des patients ou du dispositif sont peu nombreuses. Du fait de la grande disponibilitĂ© de ces dispositifs et de lâĂ©quipement rapide des centres, le groupe « unitĂ© de soins intensifs cardiologiques » de la sociĂ©tĂ© française de cardiologie a voulu proposer un algorithme pratique dâutilisation pour aider les mĂ©decins de soins intensifs dans ce domaine oĂč les donnĂ©es scientifiques sont rares. Previous article in issu
An unusual left anterior descending artery myocardial bridging
International audienceNo abstract availabl
Ătude clinique sur lâassistance circulatoire par pompe microaxiale dans le choc cardiogĂ©nique compliquant un infarctus du myocarde : mission impossible ?
International audienceCardiogenic shock is a complex clinical entity associated with very high mortality and intensive resource utilization. Despite the widespread use of timely reperfusion and appropriate pharmacotherapy, the survival rate remains at around 50%. Recently, percutaneous axial flow pumps have been integrated into the therapeutic spectrum of cardiogenic shock management. However, most of the literature supporting their use stems from observational studies. To date, attempts to perform randomized controlled trials with percutaneous axial flow pumps have failed. This underlines the challenge of performing a well-conducted randomized controlled trial that provides the highest level of evidence. Such a trial is warranted, because percutaneous axial flow pumps are costly, and are associated with serious complications. The major pitfalls of previous studies were lack of standardized cardiogenic shock definitions according to clinical severity, inappropriate patient and device selection, lack of standardized trial endpoints and high rates of crossovers; these issues must be carefully considered and evaluated. In light of recent trial failures, we aim to summarize the challenges associated with performing randomized controlled trials of percutaneous axial flow pumps in patients experiencing acute myocardial infarction complicated by cardiogenic shock, and to suggest potential means of overcoming them.Le choc cardiogĂ©nique reste une entitĂ© clinique complexe associĂ©e avec une trĂšs haute mortalitĂ© et une utilisation intensive de ressource. MalgrĂ© la gĂ©nĂ©ralisation de la reperfusion prĂ©coce et un traitement adaptĂ©, le taux de mortalitĂ© reste Ă©levĂ©e aux alentours de 50 %. Les pompes axiales percutanĂ©es ont Ă©tĂ© rĂ©cemment intĂ©grĂ©es dans lâarsenal thĂ©rapeutique du choc cardiogĂ©nique. Cependant, la plupart des donnĂ©es de la littĂ©rature en faveur de leur utilisation sont de natures observationnelles. Ă ce jour, les tentatives de rĂ©aliser les Ă©tudes cliniques randomisĂ©es ont Ă©tĂ© des Ă©checs. Cela souligne Ă quel point il reste compliquĂ© de rĂ©aliser une Ă©tude randomisĂ©e bien conduite afin de fournir un niveau de preuve suffisant. Une telle Ă©tude est nĂ©cessaire car les pompes axiales sont coĂ»teuses et associĂ©es avec des complications sĂ©rieuses. Lâabsence de dĂ©finition standardisĂ©e du choc cardiogĂ©nique en fonction de sa gravitĂ©, une mauvaise sĂ©lection des patients ou des interventions, lâabsence de critĂšre de jugement validĂ© et le fort taux de crossover sont parmi les Ă©cueils majeurs de la rĂ©alisation des prĂ©cĂ©dentes Ă©tudes et doivent ĂȘtre prise en compte pour la rĂ©alisation des prochaines. Ă la lumiĂšre des Ă©checs rĂ©cents, nous avons voulu rĂ©sumer les Ă©cueils pour la rĂ©alisation dâune Ă©tude randomisĂ©e utilisant les pompes microaxiales dans le choc cardiogĂ©nique secondaire Ă un IDM et suggĂ©rer des voies potentielles de rĂ©solution
Relative impact of bleedings over ischaemic events in patients with heart failure: insights from the CARDIONOR registry
Abstract Aims Major bleeding events in heart failure (HF) patients are poorly described. We sought to investigate the importance of major bleeding and its impact on outcomes in HF patients. Methods and results We analysed incident bleeding and ischaemic events during a 3Â year followâup in 2910 HF outpatients included in a prospective multicentre registry. Major bleeding was defined as a Type â„3 bleed using the Bleeding Academic Research Consortium definition. Ischaemic event was a composite of ischaemic stroke and myocardial infarction. Events were adjudicated by a blinded committee. At inclusion, most patients (89%) received at least one antithrombotic: anticoagulation (53.9%) and/or antiplatelet therapy (46.2%). Bleeding occurred in 111 patients {3Â year cumulative incidence: 3.6% [95% confidence interval (CI) 3.0â4.3]} and ischaemic events in 102 patients [3Â year cumulative incidence: 3.3% (95% CI 2.7â4.0)]. Most bleedings were Bleeding Academic Research Consortium 3a (32.5%) or 3b (31.5%). Most frequent sites of bleeding were gastrointestinal (40.6%) and intracranial (27.9%). Variables associated with bleeding were atrial fibrillation [hazard ratio (HR)Â =Â 2.63 (95% CI 1.66â4.19), P <Â 0.0001], diabetes [HRÂ =Â 1.62 (95% CI 1.11â2.38), P =Â 0.012], and older age [HRÂ =Â 1.19 per 10Â year increase (95% CI 1.00â1.41), P =Â 0.049]. Anticoagulation use was associated with a twoâfold increase in the bleeding risk. Bleeding events as well as ischaemic events were strongly associated with subsequent mortality [adjusted HRs: 5.67 (4.41â7.29), P <Â 0.0001 and 4.29 (3.18â5.78), P <Â 0.0001, respectively]. Conclusions In HF outpatients, antithrombotics are widely used. Bleeding occurs at a stable rate of 1.2% annually (as frequent as ischaemic events) and is associated with a dramatic increase in mortality (at least as severe as ischaemic events). Most events occurred in patients receiving anticoagulation. Knowledge of these findings may help physicians to manage antithrombotics in HF patients
- âŠ